RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 107-108

  Dowdy, Steven F ^a   Levy, Matthew ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Vitrisa Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CELL SURFACE RECEPTOR; MESSENGER RNA; MICRORNA; OLIGONUCLEOTIDE; RNA; SMALL INTERFERING RNA; ANTISENSE OLIGONUCLEOTIDE; LIPID; NANOPARTICLE;

ANTISENSE THERAPY; DRUG CONJUGATION; EDITORIAL; ENDOSOME; GENE TARGETING; GENE THERAPY; HUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; CHEMISTRY; GENE TRANSFER; GENETICS; LIPID BILAYER; METABOLISM; NEOPLASM; PARKINSON DISEASE; PATHOLOGY; VIRUS INFECTION;

ENDOSOMES; GENE TRANSFER TECHNIQUES; HUMANS; LIPID BILAYERS; LIPIDS; MICRORNAS; NANOPARTICLES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PARKINSON DISEASE; RECEPTORS, CELL SURFACE; RNA, MESSENGER; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 85048358595     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2018.29001.dow     Document Type: Editorial

References (3)

1. Dowdy SF. (2017). Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35:222-229.
2. Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518-6548.
3. Khvorova A and JK Watts. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238-248.